Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Sanjeev Luther, President and CEO, to provide corporate overview and business outlook

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Ernexa Therapeutics, an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, announced that Sanjeev Luther, President & CEO of Ernexa, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026, at 4:00 PM ET. As part of the segment, Luther will provide a corporate overview and business outlook, and investors will have the opportunity to submit questions live during the event.

Why it matters

Ernexa Therapeutics is a promising biotech company working on innovative cell therapies for cancer and autoimmune diseases. This virtual investor event will provide an opportunity for the company to share its progress and future plans with the investment community.

The details

During the Virtual Investor Closing Bell Series, Sanjeev Luther, President & CEO of Ernexa Therapeutics, will give a presentation and participate in a moderated discussion. Investors and interested parties will also have the chance to submit questions live during the event. A webcast replay will be available for 90 days following the live presentation.

  • The Virtual Investor Closing Bell Series event will take place on Wednesday, February 25, 2026, at 4:00 PM ET.

The players

Ernexa Therapeutics

An industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease.

Sanjeev Luther

The President and Chief Executive Officer of Ernexa Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.”

— Ernexa Therapeutics (biospace.com)

What’s next

A webcast replay of the Virtual Investor Closing Bell Series event will become available two hours following the live presentation and will be accessible for 90 days.

The takeaway

Ernexa Therapeutics' participation in the Virtual Investor Closing Bell Series provides an opportunity for the company to showcase its innovative cell therapy pipeline and engage with the investment community as it continues to advance its treatments for cancer and autoimmune diseases.